Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders
(Thomson Reuters ONE) -
Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders
Herantis Pharma Plc
Company release 11 April 2016 at 5:00 PM
The Annual General Meeting of Shareholders of Herantis Pharma Plc was held in
Helsinki on Monday, 11 April 2016.
Matters pertaining to the Annual General Meeting
The Annual General Meeting adopted the consolidated financial statements and the
parent company's financial statements for the financial year 2015 and discharged
the members of the Board of Directors and the CEO from liability. The Annual
General Meeting of Shareholders decided that, as proposed by the Board of
Directors, no dividend be paid for the financial year 1 January - 31 December
2015 and that the loss for the financial year shall be entered in the
compilation of loss.
The Annual General Meeting resolved that the remuneration payable to the members
of the Board of Directors shall be EUR 1,000 per month except for the Chairman
of the Board who shall be paid EUR 2,000 monthly. It was further resolved that
the board members shall also be eligible to subscribe to stock options of option
program 2014 I, according to the rules of which the board members can be given
stock options for each full 12 month period as a Board member.
The Annual General Meeting decided that the Auditor will be paid reasonable
remuneration in accordance with the invoice approved by the Company.
The firm of authorised public accountants PricewaterhouseCoopers Oy was
appointed as Herantis Pharma Plc's Auditor for the term ending at the end of the
next Annual General Meeting of Shareholders, with APA Martin Grandell as the
responsible auditor.
HERANTIS PHARMA PLC
Further information:
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246
About Herantis Pharma Plc
Herantis Pharma Plc is a drug development company focused on early clinical
development of innovative drugs in unmet clinical needs. Our special emphasis is
in regenerative medicine where the company has two first-in-class assets based
on globally leading science in their fields: CDNF for neurodegenerative
diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer
associated lymphedema, with potential also in primary lymphedema. The shares of
Herantis are listed on the First North Finland marketplace run by Nasdaq
Helsinki stock exchange.
Distribution:
Nasdaq Helsinki
Main media
www.herantis.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Herantis Pharma Oyj via GlobeNewswire
[HUG#2002369]
Unternehmensinformation / Kurzprofil:
Datum: 11.04.2016 - 16:00 Uhr
Sprache: Deutsch
News-ID 463171
Anzahl Zeichen: 3490
contact information:
Town:
Helsinki
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Herantis Pharma Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
